You are here

Overview

History

In 2001, the late President George H.W. Bush, the forty-first President of the United States, asked Robert A. Ingram, then the CEO of GlaxoWellcome, to convene and chair the CEO Roundtable on Cancer in support of an historic initiative known as C-Change. Until 2016, C-Change (formerly called the National Dialogue on Cancer), was a national forum that brought together key cancer leaders from government, business, academia and nonprofit sectors, all of whom shared a common vision: eliminating cancer.

Specifically, President Bush asked Bob Ingram to form a separate organization, comprised of action-oriented chief executives, and challenged them to "do something more about cancer prevention, diagnosis, and treatment within your own family as well as within your corporate family."

President Bush also requested that Dr. Martin J. Murphy, an NIH principal investigator and founding Executive Editor of several peer-reviewed journals that focused on oncology and stem cells, take the role as Founding CEO of the Roundtable on Cancer, a position he held until January 2020.

Mission

Today, the CEO Roundtable on Cancer, chartered as a 501(c)(3) nonprofit organization in 2005, works to develop and implement initiatives that reduce the risk of cancer, enable early diagnosis, facilitate access to the best available treatments, and hasten the discovery of novel and more effective anti-cancer therapies to help eliminate cancer as a personal disease and public health problem.

Programs

The CEO Roundtable on Cancer has responded to President Bush's call to action with the following programs:

  • CEO Cancer Gold Standard™ – An employer-led, wellness accreditation program addressing prevention, diagnosis and quality treatment

  • Project Data Sphere – As a convener, collaborator, and catalyst, we leverage experts spanning industry, academia, and government to achieve our mutual goals of improving cancer trials in order to expedite drug discovery. A key offering is our digital library-laboratory to share, integrate, and analyze clinical trial data.